

KEWAUNEE SCIENTIFIC CORP /DE/

Form 10-Q

March 15, 2011

Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 10-Q**

x **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended January 31, 2011

or

.. **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-5286

**KEWAUNEE SCIENTIFIC CORPORATION**

(Exact name of registrant as specified in its charter)

|  |   |
|--|---|
| <b>Delaware</b><br>(State or other jurisdiction of<br>incorporation or organization) | <b>38-0715562</b><br>(IRS Employer<br>Identification No.) |
| <b>2700 West Front Street</b>  |   |
| <b>Statesville, North Carolina</b><br>(Address of principal executive offices)       | <b>28677-2927</b><br>(Zip Code)                           |
| <b>Registrant's telephone number, including area code: (704) 873-7202</b>            |   |

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

|  |   |
|--|---|
| Large accelerated filer <input type="checkbox"/>   | Accelerated filer <input type="checkbox"/>                    |
| Non-accelerated filer <input type="checkbox"/> (Do not check if a smaller reporting company) | Smaller reporting company <input checked="" type="checkbox"/> |

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes  No

As of March 11, 2011, the registrant had outstanding 2,578,270 shares of Common Stock.

---

**Table of Contents**

**KEWAUNEE SCIENTIFIC CORPORATION**

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2011

|  | <b>Page Number</b> |
|--|--------------------|
| <b><u>PART I. FINANCIAL INFORMATION</u></b>  |                    |
| Item 1. <u>Financial Statements</u>  |                    |
| <u>Consolidated Statements of Operations – Three and Nine months ended January 31, 2011 and 2010</u> | 1                  |
| <u>Consolidated Balance Sheets – January 31, 2011 and April 30, 2010</u>                             | 2                  |
| <u>Consolidated Statements of Cash Flows – Nine months ended January 31, 2011 and 2010</u>           | 3                  |
| <u>Notes to Consolidated Financial Statements</u>  | 4                  |
| Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> | 7                  |
| <u>Review by Independent Registered Public Accounting Firm</u>                                       | 9                  |
| <u>Report of Independent Registered Public Accounting Firm</u>                                       | 10                 |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>                            | 11                 |
| Item 4. <u>Controls and Procedures</u>   | 11                 |
| <b><u>PART II. OTHER INFORMATION</u></b>   |                    |
| Item 6. <u>Exhibits</u>  | 12                 |
| <u>SIGNATURE</u>   | 13                 |

**Table of Contents**

## Part 1. Financial Information

**Item 1. Financial Statements***Kewaunee Scientific Corporation*

## Consolidated Statements of Operations

*(Unaudited)**(in thousands, except per share data)*

|   | Three months ended<br>January 31 |           | Nine months ended<br>January 31 |           |
|---|----------------------------------|-----------|---------------------------------|-----------|
|   | 2011                             | 2010      | 2011                            | 2010      |
| Net Sales   | \$ 22,568                        | \$ 21,814 | \$ 73,051                       | \$ 75,151 |
| Costs of products sold  | 18,405                           | 17,129    | 58,472                          | 58,492    |
| Gross profit  | 4,163                            | 4,685     | 14,579                          | 16,659    |
| Operating expenses  | 4,007                            | 3,663     | 11,953                          | 11,605    |
| Operating earnings  | 156                              | 1,022     | 2,626                           | 5,054     |
| Other expense   | 1                                |           |                                 |           |
| Interest income (expense)   | 17                               | (35)      | (105)                           | (115)     |
| Earnings before income taxes  | 174                              | 987       | 2,521                           | 4,939     |
| Income tax expense  | 49                               | 333       | 792                             | 1,673     |
| Net earnings  | 125                              | 654       | 1,729                           | 3,266     |
| Less: net earnings attributable to the noncontrolling interest                      | 39                               | 33        | 131                             | 222       |
| Net earnings attributable to Kewaunee Scientific Corporation                        | \$ 86                            | \$ 621    | \$ 1,598                        | \$ 3,044  |
| Net earnings per share attributable to Kewaunee Scientific Corporation stockholders |                                  |           |                                 |           |
| Basic   | \$ 0.03                          | \$ 0.24   | \$ 0.62                         | \$ 1.19   |
| Diluted   | \$ 0.03                          | \$ 0.24   | \$ 0.62                         | \$ 1.18   |
| Weighted average number of common shares outstanding (in thousands)                 |                                  |           |                                 |           |
| Basic   | 2,576                            | 2,569     | 2,574                           | 2,562     |
| Diluted   | 2,592                            | 2,581     | 2,583                           | 2,570     |

*See accompanying notes to consolidated financial statements.*

**Table of Contents***Kewaunee Scientific Corporation*

## Consolidated Balance Sheets

*(in thousands)*

|  | January 31,<br>2011<br>(Unaudited) | April 30,<br>2010 |
|--|------------------------------------|-------------------|
| <b><u>Assets</u></b>                       |                                    |                   |
| Current assets:                            |                                    |                   |
| Cash and cash equivalents                  | \$ 2,160                           | \$ 1,722          |
| Restricted cash                            | 544                                | 544               |
| Receivables, less allowance                | 21,056                             | 26,169            |
| Inventories                                | 10,521                             | 8,350             |
| Deferred income taxes                      | 444                                | 390               |
| Prepaid expenses and other current assets  | 1,387                              | 1,407             |
| <b>Total current assets</b>                | <b>36,112</b>                      | <b>38,582</b>     |
| Property, plant and equipment, at cost     | 46,609                             | 43,200            |
| Accumulated depreciation                   | (29,912)                           | (29,385)          |
| <b>Net property, plant and equipment</b>   | <b>16,697</b>                      | <b>13,815</b>     |
| Deferred income taxes                      | 738                                | 663               |
| Other                                      | 3,645                              | 3,561             |
| <b>Total other assets</b>                  | <b>4,383</b>                       | <b>4,224</b>      |
| <b>Total Assets</b>                        | <b>\$ 57,192</b>                   | <b>\$ 56,621</b>  |
| <b><u>Liabilities and Equity</u></b>       |                                    |                   |
| Current liabilities:                       |                                    |                   |
| Short-term borrowings                      | \$ 696                             | \$ 4,872          |
| Current obligations under capital leases   | 81                                 | 82                |
| Current portion of long-term debt          | 200                                |                   |
| Accounts payable                           | 8,415                              | 9,540             |
| Employee compensation and amounts withheld | 1,781                              | 1,358             |
| Deferred revenue                           | 1,003                              | 586               |
| Other accrued expenses                     | 2,595                              | 2,059             |
| <b>Total current liabilities</b>           | <b>14,771</b>                      | <b>18,497</b>     |
| Obligations under capital leases           | 58                                 | 119               |
| Long-term debt                             | 3,717                              |                   |
| Accrued employee benefit plan costs        | 6,104                              | 6,333             |
| <b>Total Liabilities</b>                   | <b>24,650</b>                      | <b>24,949</b>     |
| Equity:                                    |                                    |                   |
| Common Stock                               | 6,550                              | 6,550             |
| Additional paid-in-capital                 | 1,010                              | 855               |
| Retained earnings                          | 29,224                             | 28,398            |
| Accumulated other comprehensive loss       | (5,150)                            | (4,898)           |
| Common stock in treasury, at cost          | (441)                              | (472)             |

Edgar Filing: KEWAUNEE SCIENTIFIC CORP /DE/ - Form 10-Q

|  |           |           |
|--|-----------|-----------|
| Total Kewaunee Scientific Corporation stockholders' equity | 31,193    | 30,433    |
| Noncontrolling interest                                    | 1,349     | 1,239     |
| Total Equity   | 32,542    | 31,672    |
| Total Liabilities and Equity                               | \$ 57,192 | \$ 56,621 |

*See accompanying notes to consolidated financial statements.*

**Table of Contents***Kewaunee Scientific Corporation*

## Consolidated Statements of Cash Flows

*(Unaudited)**(in thousands)*

|   | <b>Nine months ended<br/>January 31</b> |                 |
|---|---|-----------------|
|   | <b>2011</b>                             | <b>2010</b>     |
| <b><i>Cash flows from operating activities:</i></b>                                 |   |                 |
| Net earnings  | \$ 1,729                                | \$ 3,266        |
| Adjustments to reconcile net earnings to net cash provided by operating activities: |   |                 |
| Depreciation  | 1,816                                   | 1,840           |
| Bad debt provision  | 19                                      | 107             |
| Provision for deferred income tax expense   | (129)                                   | (21)            |
| Decrease in prepaid income taxes  |   | 9               |
| Decrease in receivables   | 5,094                                   | 1,412           |
| Increase in inventories   | (2,171)                                 | (85)            |
| Decrease in accounts payable and other accrued expenses                             | (166)                                   | (1,506)         |
| Increase (decrease) in deferred revenue   | 417                                     | (590)           |
| Other, net  | (474)                                   | 595             |
| Net cash provided by operating activities   | 6,135                                   | 5,027           |
| <b><i>Cash flows from investing activities:</i></b>                                 |   |                 |
| Capital expenditures  | (4,698)                                 | (3,080)         |
| Increase in restricted cash   |   | (50)            |
| Net cash used in investing activities   | (4,698)                                 | (3,130)         |
| <b><i>Cash flows from financing activities:</i></b>                                 |   |                 |
| Proceeds from long-term debt  | 4,000                                   |                 |
| Payments on long-term debt  | (83)                                    |                 |
| Dividends paid  | (772)                                   | (719)           |
| Decrease in short-term borrowings   | (4,176)                                 | (2,811)         |
| Payments on capital leases  | (62)                                    | (186)           |
| Purchase of treasury stock  | (68)                                    | (245)           |
| Proceeds from exercise of stock options (including tax benefit)                     | 99                                      | 267             |
| Net cash used in financing activities   | (1,062)                                 | (3,694)         |
| Effect of exchange rate changes on cash and cash equivalents                        | 63                                      | 175             |
| <b><i>Increase (decrease) in cash and cash equivalents</i></b>                      | <b>438</b>                              | <b>(1,622)</b>  |
| <b><i>Cash and cash equivalents, beginning of period</i></b>                        | <b>1,722</b>                            | <b>3,559</b>    |
| <b><i>Cash and cash equivalents, end of period</i></b>                              | <b>\$ 2,160</b>                         | <b>\$ 1,937</b> |

*See accompanying notes to consolidated financial statements*



**Table of Contents**

## Kewaunee Scientific Corporation

## Notes to Consolidated Financial Statements

(unaudited)

**A. Financial Information**

The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the Company or Kewaunee) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the Commission). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's 2010 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

The preparation of the interim consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

**B. Inventories**

Inventories consisted of the following (in thousands):

|                   | <b>January 31, 2011</b> | <b>April 30, 2010</b> |
|-------------------|-------------------------|-----------------------|
| Finished products | \$ 2,828                | \$ 2,199              |
| Work in process   | 1,599                   | 1,237                 |
| Raw materials     | 6,094                   | 4,914                 |
|                   | \$ 10,521               | \$ 8,350              |

For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim consolidated financial statements in the period in which they occur.

**C. Comprehensive Income**

A reconciliation of net earnings and total comprehensive income for the three and nine months ended January 31, 2011 and 2010 is as follows (in thousands):

|   | <b>Three months ended<br/>January 31,<br/>2011</b> | <b>Three months ended<br/>January 31,<br/>2010</b> |
|---|--|--|
| Net earnings  | \$ 86  | \$ 621   |
| Change in cumulative foreign currency translation adjustments | (133)  | 39   |
| Change in fair value of cash flow hedge, net of tax           | 107  | (29)   |
| Total comprehensive income                                    | \$ 60  | \$ 631   |

|   | Nine months ended<br>January 31,<br>2011 | Nine months ended<br>January 31, 2010 |
|---|--|---------------------------------------|
| Net earnings  | \$ 1,598                                 | \$ 3,044                              |
| Change in cumulative foreign currency translation adjustments | (151)                                    | 252                                   |
| Change in fair value of cash flow hedge, net of tax           | (101)                                    | (29)                                  |
| <br>Total comprehensive income                                | <br>\$ 1,346                             | <br>\$ 3,267                          |

Assets and liabilities for the Company's foreign subsidiaries are translated at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at weighted average exchange rates prevailing during the period and any resulting translation adjustments are reported separately in stockholders' equity.

**Table of Contents****D. Segment Information**

The following table provides financial information by business segments for the three and nine months ended January 31, 2011 and 2010 (in thousands):

|  | Domestic<br>Operations | International<br>Operations | Corporate | Total     |
|--|------------------------|-----------------------------|-----------|-----------|
| <b>Three months ended January 31, 2011</b>     |                        |                             |           |           |
| Revenues from external customers               | \$ 19,108              | \$ 3,460                    | \$        | \$ 22,568 |
| Intersegment revenues                          | 1,054                  | 96                          | (1,150)   |           |
| Operating earnings (loss) before income taxes  | 774                    | 148                         | (748)     | 174       |
| <b>Three months ended January 31, 2010</b>     |                        |                             |           |           |
| Revenues from external customers               | \$ 19,081              | \$ 2,733                    | \$        | \$ 21,814 |
| Intersegment revenues                          | 477                    | 23                          | (500)     |           |
| Operating earnings (loss) before incomes taxes | 1,538                  | 127                         | (678)     | 987       |
| <b>Nine months ended January 31, 2011</b>      |                        |                             |           |           |
| Revenues from external customers               | \$ 62,324              | \$ 10,727                   | \$        | \$ 73,051 |
| Intersegment revenues                          | 2,222                  | 743                         | (2,965)   |           |
| Operating earnings (loss) before incomes taxes | 4,470                  | 481                         | (2,430)   | 2,521     |
| <b>Nine months ended January 31, 2010</b>      |                        |                             |           |           |
| Revenues from external customers               | \$ 67,152              | \$ 7,999                    | \$        | \$ 75,151 |
| Intersegment revenues                          | 1,169                  | 441                         | (1,610)   |           |
| Operating earnings (loss) before incomes taxes | 6,984                  | 636                         | (2,681)   | 4,939     |

**E. Defined Benefit Pension Plans**

The Company has non-contributory defined benefit pension plans covering substantially all salaried and hourly employees. These plans were amended as of April 30, 2005, no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. Contributions of \$719,000 were paid to the plans during the nine months ended January 31, 2011, and the Company does not expect any contributions to be paid to the plans during the remainder of the current fiscal year. No contributions were made during the comparable periods of the prior year.

Pension expense consisted of the following (in thousands):

|                                     | Three months ended<br>January 31,<br>2011         | Three months ended<br>January 31,<br>2010     |
|-------------------------------------|---|---|
| Service cost                        | \$ -0-  | \$ -0-  |
| Interest cost                       | 240   | 238   |
| Expected return on plan assets      | (289)   | (235)   |
| Recognition of net loss             | 172   | 174   |
| <b>Net periodic pension expense</b> | <b>\$ 123</b>                                     | <b>\$ 177</b>                                 |
|                                     | <b>Nine months ended<br/>January 31,<br/>2011</b> | <b>Nine months ended<br/>January 31, 2010</b> |
| Service cost                        | \$ -0-  | \$ -0-  |
| Interest cost                       | 720   | 713   |
| Expected return on plan assets      | (867)   | (704)   |
| Recognition of net loss             | 516   | 521   |

|                              |    |     |    |     |
|------------------------------|----|-----|----|-----|
| Net periodic pension expense | \$ | 369 | \$ | 530 |
|------------------------------|----|-----|----|-----|

F. Credit Arrangement

In July 2009, the Company amended its unsecured revolving credit facility to extend the facility's expiration date to July 31, 2012, and modify the variable rate component of the interest calculation. Monthly interest payments under the facility, as amended, are calculated at the 30-day LIBOR Market Interest Rate plus a variable rate ranging from 1.575% to 2.175%.

In July 2009, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on \$2 million of outstanding advances under the revolving credit facility was effectively converted to a fixed interest rate of 3.9% for the period beginning August 3, 2009, and ending August 1, 2012. The Company entered into this interest rate swap to mitigate future interest rate risk associated with advances under the credit facility.

## **Table of Contents**

### **G. Long-Term Debt**

On August 2, 2010, the Company amended its existing bank agreement covering its unsecured \$14 million revolving credit facility to provide for an additional \$4 million seven-year term loan secured by the Company's real property and equipment located in Statesville, North Carolina. The term loan requires monthly principal payments of approximately \$17,000, plus interest calculated at the 30-day LIBOR Market Index Rate plus 1.575%, with payment of the outstanding principal balance and any unpaid interest at the term loan maturity date. In June 2010, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on the term loan was effectively converted to a fixed interest rate of 4.875%, effective August 2, 2010. The term loan includes financial covenants similar to the unsecured revolving credit facility. The proceeds of the term loan were used primarily to fund the expansion of the Company's Statesville, North Carolina manufacturing facilities.

### **H. Derivative Instruments and Hedging Activities**

As described in Note G above, the Company entered into an interest rate swap agreement with an initial notional amount of \$4 million, whereby the interest rate payable by the Company on the unpaid balance of the new term loan is effectively converted to a fixed interest rate of 4.875% for the period beginning August 2, 2010, and ending August 1, 2017. The Company entered into this interest rate swap to mitigate future interest rate risk associated with advances under the credit facility. The Company does not use derivatives for trading or speculative purposes. The effective portion of changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income (loss) and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. The Company did not record any hedge ineffectiveness in earnings during the three months and nine months periods ended January 31, 2011 and 2010.

The fair value of cash flow hedges at January 31, 2011 was recorded in the Company's consolidated balance sheet as a current liability of \$211,000 and accumulated other comprehensive loss of \$132,000, net of deferred tax of \$79,000. See Note C for the change in fair value for the three and nine month periods ended January 31, 2011 and 2010.

### **I. Reclassifications**

Certain 2010 amounts have been reclassified to conform with the 2011 presentation in the consolidated statements of cash flows. Such reclassifications had no impact on net earnings.

---

**Table of Contents****Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The Company's 2010 Annual Report to Stockholders contains management's discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2010. The following discussion and analysis describes material changes in the Company's financial condition since April 30, 2010. The analysis of results of operations compares the three and nine months ended January 31, 2011 with the comparable periods of the prior fiscal year.

**Results of Operations**

Sales for the three months ended January 31, 2011 were \$22,568,000, up 3.5% from sales of \$21,814,000 in the third quarter last year. Sales for the quarter were unfavorably affected when customers made changes to product designs and delivery dates for several significant orders, including one large international order, that delayed the start of manufacturing and shipment until late in the quarter and into the fourth quarter. Sales also reflect a continuing softness in the domestic marketplace for small and mid-sized laboratory projects. Domestic sales were \$19,108,000, relatively flat from \$19,081,000 in the third quarter last year, while international sales were \$3,460,000, up from \$2,733,000 in the third quarter last year.

Sales for the nine months ended January 31, 2011 were \$73,051,000, down 2.8% from sales of \$75,151,000, in the same period last year. Domestic operations sales were \$62,324,000, down from sales of \$67,152,000 in the same period last year. International operations sales were \$10,727,000, up from sales of \$7,999,000 in the same period last year.

The order backlog was \$68.2 million at January 31, 2011, as compared to \$66.0 million at October 31, 2010 and \$65.5 million at January 31, 2010.

The gross profit margin for the three months ended January 31, 2011 was 18.4% of sales, as compared to 21.5% of sales in the comparable quarter of the prior year. The gross profit margin for the nine months ended January 31, 2011 was 20.0% of sales, as compared to 22.2% of sales in the comparable quarter of the prior year. The decreases in gross profit margin percentages for the current year periods were primarily due to aggressive pricing in all of the Company's markets, increased manufacturing costs resulting from changes in production schedules caused by customer changes in product requirements and delivery dates, an unfavorable product mix, and higher prices paid for epoxy resin raw materials, which are petroleum-based products.

Operating expenses for the three months ended January 31, 2011 were \$4,007,000, or 17.8% of sales, as compared to \$3,663,000, or 16.8% of sales, in the comparable period of the prior year. The ratio of operating expenses to sales increased for the three months ended January 31, 2011 primarily due to growth in the Company's international operations and higher costs for compensation and benefits. Operating expenses for the nine months ended January 31, 2011 were \$11,953,000, or 16.4% of sales, as compared to \$11,605,000, or 15.4% of sales, in the comparable period of the prior year. The ratio of operating expenses to sales increased for the nine months ended January 31, 2011 primarily due to growth in the Company's international operations while the sales figure in the ratio declined.

Operating earnings were \$156,000 and \$2,626,000 for the three and nine months ended January 31, 2011. This compares to operating earnings of \$1,022,000 and \$5,054,000 for the comparable periods of the prior year.

Net interest income/expense was interest income of \$17,000 and interest expense of \$105,000 for the three and nine months ended January 31, 2011, respectively, as compared to interest expense of \$35,000 and \$115,000 for the comparable periods of the prior year. The changes in interest expense for the current year periods resulted primarily from lower short-term borrowings.

Income tax expense of \$49,000 and \$792,000 was recorded for the three and nine months ended January 31, 2011, respectively, as compared to income tax expense of \$333,000 and \$1,673,000 recorded for the comparable periods of the prior year. The effective tax rates were 28.2% and 31.4% for the three and nine months ended January 31, 2011, respectively, and were 33.7% and 33.9% for the three and nine months ended January 31, 2010. The effective tax rates for each of the three and nine month periods differs from the statutory rate primarily due to the impact of varying income tax rates on income earned by the Company's foreign subsidiaries and the impact of earned state and federal tax credits. The decrease in the effective tax rates in the current year periods as compared to the prior year periods resulted primarily from the fact that the higher pre-tax earnings levels in the prior year periods were less impacted by earned state and federal tax credits.

Net earnings attributable to the noncontrolling interest related to the Company's two subsidiaries that are not 100% owned by the Company were \$39,000 and \$131,000 for the three and nine months ended January 31, 2011, respectively, as compared to \$33,000 and \$222,000, respectively, for the comparable periods of the prior year. The changes in the net earnings attributable to the noncontrolling interest were due to slightly higher earnings of the two subsidiaries in the three months ended January 31, 2011 and due to lower earnings for those subsidiaries in the nine months ended January 31, 2011, as compared to the similar prior year periods.

## Edgar Filing: KEWAUNEE SCIENTIFIC CORP /DE/ - Form 10-Q

Net earnings for the three months ended January 31, 2011 were \$86,000, or \$0.03 per diluted share, a decrease from net earnings of \$621,000, or \$0.24 per diluted share, in the third quarter of the prior year. Net earnings for the nine months were \$1,598,000, or \$0.62 per diluted share, down from net earnings of \$3,044,000, or \$1.18 per diluted share, for the same period last year. Earnings for the three and nine month periods of the current year were unfavorably impacted by continued aggressive pricing in all of the Company's markets, increased manufacturing costs, an unfavorable product mix, and high prices paid for epoxy resin raw materials.

---

## Table of Contents

### Liquidity and Capital Resources

Historically, the Company's principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company's revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancellable operating leases or capital leases. The Company believes that these sources will be sufficient to support ongoing business requirements, including capital expenditures through the current fiscal year.

The Company had working capital of \$21,341,000 at January 31, 2011, compared to \$20,085,000 at April 30, 2010. The ratio of current assets to current liabilities was 2.4-to-1.0 at January 31, 2011, compared to 2.1-to-1.0 at April 30, 2010. At January 31, 2011, advances of \$696,000 were outstanding under the Company's bank revolving credit facility, as compared to advances of \$4,872,000 outstanding as of April 30, 2010. Total bank borrowings and capital lease obligations were \$4,752,000 at January 31, 2011, as compared to \$5,073,000 at April 30, 2010.

The Company's operations provided cash of \$6,135,000 during the nine months ended January 31, 2011. Cash was primarily provided from a reduction of \$5,094,000 in receivables and from operating earnings, partially offset by an increase in inventories of \$2,171,000. The Company's operations provided cash of \$5,027,000 during the nine months ended January 31, 2010, with cash primarily provided from operating earnings and a reduction of \$1,412,000 in receivables, partially offset by a decrease of \$1,506,000 in accounts payable and accrued expenses.

During the nine months ended January 31, 2011, net cash of \$4,698,000 was used in investing activities, primarily for capital expenditures related to the expansion of the Company's Statesville, North Carolina manufacturing facilities. This compares to the use of \$3,130,000 for investing activities in the comparable period of the prior year, primarily for capital expenditures.

The Company's financing activities used cash of \$1,062,000 during the nine months ended January 31, 2011. Uses of cash include \$4,176,000 for repayment of short-term borrowings, \$772,000 for cash dividends, \$83,000 for payments on long-term debt, and \$62,000 for payments on obligations of capital leases. Cash of \$4,000,000 was provided from new long-term debt, as discussed in Note G, to fund the expansion of the Statesville manufacturing facilities. Financing activities used cash of \$3,694,000 in the same period for the prior year, which included \$2,811,000 for repayments of short-term borrowings, \$719,000 for payments of cash dividends, and \$186,000 for payments on obligations of capital leases.

### Outlook for Fourth Quarter of Fiscal Year 2011

The Company's ability to predict future demand for its products continues to be limited given, among other general economic factors affecting the Company and its markets, the Company's role as subcontractor or supplier to dealers for subcontractors, and the fact that demand for its products is dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. Customer changes to product designs and delivery dates for orders may also delay the start of manufacturing and shipment of orders, which in return may impact the timing of sales revenue and increase manufacturing costs.

The Company expects that sales and earnings for the fourth quarter of fiscal year 2011 will likely improve over the third quarter of the fiscal year. The Company's expectations are based on a number of factors, including the projected manufacturing and shipment of several orders that were delayed in the third quarter, an expected improved product mix over the third quarter, and the scheduled delivery dates for order in the order backlog.

### Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements in this report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the Reform Act). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company's operations, customer changes to product designs, customer changes to delivery dates, markets, products, services, and prices, as well as prices for certain raw materials and energy. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms believes, belief, expects, plans, objectives, anticipate, intends or the like to be uncertain and forward-looking. Over time, the Company's actual results, performance or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by the Company's forward-looking statements, and such difference might be significant and harmful to stockholders' interests. Many important factors that could cause such a difference are described under the caption Risk Factors, in Item 1A of the Company's 2010 Annual Report on Form 10-K.



**Table of Contents**

REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

A review of the interim consolidated financial information included in this Quarterly Report on Form 10-Q for each of the three and nine month periods ended January 31, 2011 and January 31, 2010 has been performed by Cherry, Bekaert & Holland, L.L.P., the Company's independent registered public accounting firm. Their report on the interim consolidated financial information follows.

**Table of Contents**

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have reviewed the accompanying consolidated balance sheet of Kewaunee Scientific Corporation and its subsidiaries (the Company) as of January 31, 2011, and the related consolidated statements of operations for the three month and nine month periods ended January 31, 2011 and 2010 and the related consolidated statements of cash flows for the nine-month periods ended January 31, 2011 and 2010. These interim consolidated financial statements are the responsibility of the Company's management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the interim consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet as of April 30, 2010, and the related statements of operations, of stockholders' equity and of cash flows for the year then ended (not presented herein) and in our report dated July 16, 2010, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of April 30, 2010 is fairly stated in all material respects in relation to the consolidated financial statement from which it has been derived.

/s/ Cherry, Bekaert & Holland, L.L.P.

Charlotte, North Carolina

March 11, 2011

**Table of Contents**

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

There are no material changes to the disclosures made on this matter in the Company's Annual Report on Form 10-K for the fiscal year ended April 30, 2010.

**Item 4. Controls and Procedures**

(a) Evaluation of disclosure controls and procedures

An evaluation was performed under the supervision and the participation of the Company's management, including the Chief Executive Officer ( CEO ) and Chief Financial Officer ( CFO ), of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of January 31, 2011. Based on that evaluation, the Company's management, including the CEO and CFO, concluded that, as of January 31, 2011, the Company's disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

(b) Changes in internal controls

There was no significant change in the Company's internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

**Table of Contents**

PART II. OTHER INFORMATION

**Item 6. Exhibits**

- 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

**Table of Contents**

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KEWAUNEE SCIENTIFIC CORPORATION

(Registrant)

Date: March 15, 2011

By /s/ D. Michael Parker  
D. Michael Parker

(As duly authorized officer and Senior Vice President, Finance and  
Chief Financial Officer)

13